“Regarding the production of antibodies after vaccination with the EpiVacCorona vaccine, Rspotrebnadzor informs that vaccination with peptide antigens is characterized by a smaller variety of forming antibodies,” the statement said, published on the agency’s website.
Rospotrebnadzor explained that “most of the commercial test kits are aimed at detecting a wide range of antibodies to different parts of the S envelope protein of the new coronavirus, and their sensitivity may not be enough to detect a small pool of key antibodies formed after vaccination with the EpiVacCorona vaccine.
“In this regard, to assess the level formed after the introduction of the vaccine of immunity, it is necessary to use special ELISA test systems“ SARS-CoV-2-IgG-Vector, ”the department said.
Rospotrebnadzor added that these test systems are supplied to all regions where EpiVacKorona vaccination is carried out.
Earlier, the head of the Russian Ministry of Health, Mikhail Murashko, said that the EpiVacCorona vaccine developed by the Vector Center began to arrive at the country's medical institutions this week.
According to data as of April 3, in Russia, during the day, coronavirus infection COVID-19 was confirmed in 9021 people.
The total number of infections reached 4,572,077.
Irina Yartseva, a member of the European Society of Allergists and Clinical Immunologists, therapist and immunologist, in an interview with FAN, assessed the situation with the pandemic in Russia.